MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD |
Song, Hongming
(Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Li, Dengfeng (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Wu, Tianqi (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Xie, Dan (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Hua, Kaiyao (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Hu, Jiashu (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Deng, Xiaochong (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Ji, Changle (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Deng, Yijun (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) Fang, Lin (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University) |
1 | Dawood S (2010) Triple-negative breast cancer: epidemiology and management options. Drugs 70, 2247-2258 DOI |
2 | Lee A and Djamgoz MBA (2018) Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62, 110-122 DOI |
3 | Fkih M'hamed I, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ and Kenani A (2017) miR-10b, miR-26a, miR-146a and miR-153 expression in triple negative vs non triple negative breast cancer: Potential biomarkers. Pathol Oncol Res 23, 815-827 DOI |
4 | Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34, D140-144 DOI |
5 | Ardekani AM and Naeini MM (2010) The role of microRNAs in human diseases. Avicenna J Med Biotechnol 2, 161-179 |
6 | Tufekci KU, Meuwissen RL and Genc S (2014) The role of microRNAs in biological processes. Methods Mol Biol 1107, 15-31 |
7 | Calin GA, Sevignani C, Dumitru CD et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101, 2999-3004 DOI |
8 | Wu D, Chen B, Cui F, He X, Wang W and Wang M (2016) Hypoxia-induced microRNA-301b regulates apoptosis by targeting Bim in lung cancer. Cell Prolif 49, 476-483 DOI |
9 | Funamizu N, Lacy CR, Parpart ST, Takai A, Hiyoshi Y and Yanaga K (2014) MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells. Int J Oncol 44, 725-734 DOI |
10 | Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18, 621-663 DOI |
11 | Li Q and Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2, 725-734 DOI |
12 | Brummelkamp TR, Nijman SM, Dirac AM and Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424, 797-801 DOI |
13 | Yamaguchi N, Ito T, Azuma S et al (2009) Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 100, 1668-1674 DOI |
14 | Biswas DK, Shi Q, Baily S et al (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101, 10137-10142 DOI |
15 | Sovak MA, Bellas RE, Kim DW et al (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100, 2952-2960 DOI |
16 | Zhou Y, Eppenberger-Castori S, Marx C et al (2005) Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37, 1130-1144 DOI |
17 | Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801-805 DOI |
18 | Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793-796 DOI |
19 | Hayashi M, Jono H, Shinriki S et al (2014) Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 143, 447-457 DOI |
20 | Liu M, Sakamaki T, Casimiro MC et al (2010) The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 70, 10464-10473 DOI |
21 | Song HM, Song JL, Li DF, Hua KY, Zhao BK and Fang L (2015) Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway. Onco Targets Ther 8, 3565-3573 |
22 | Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ (2010) Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11, 50-54 DOI |
23 | Sun SC (2010) CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17, 25-34 DOI |
24 | Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R and Bosserhoff AK (2007) Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28, 21-27 DOI |
25 | Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M and Sif S (2005) The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol 25, 7953-7965 DOI |
26 | Massoumi R, Kuphal S, Hellerbrand C et al (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206, 221-232 DOI |